WO2008133129A1 - アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤 - Google Patents
アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤 Download PDFInfo
- Publication number
- WO2008133129A1 WO2008133129A1 PCT/JP2008/057394 JP2008057394W WO2008133129A1 WO 2008133129 A1 WO2008133129 A1 WO 2008133129A1 JP 2008057394 W JP2008057394 W JP 2008057394W WO 2008133129 A1 WO2008133129 A1 WO 2008133129A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ring
- glaucoma
- adenosine
- therapeutic agent
- Prior art date
Links
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 title abstract 2
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 239000002465 adenosine A2a receptor agonist Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010030043 Ocular hypertension Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- ZOTHAEBAWXWVID-HXEFRTELSA-N uk-432,097 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C(=O)NCCNC(=O)NC3CCN(CC3)C=3N=CC=CC=3)=NC(NCC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 ZOTHAEBAWXWVID-HXEFRTELSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
アデノシンＡ２Ａ受容体アゴニストである、ＧＷ－３２８２６７、ＵＫ－４３２０９７、若しくは、下記一般式（１）で表される化合物又はその塩は、眼圧下降試験において、いずれも優れた眼圧下降効果を発揮し、緑内障若しくは高眼圧症の予防又は治療剤として有用である。Ｗは水素原子又は下記一般式（８）を示し、；環Ａはベンゼン環、ピリジン環、ピラゾール環、イミダゾール環、シクロヘキサン環等を示し、；Ｘは単結合、Ｏ－ＣＨ２－ＣＨ２、ＮＨ－ＮＨ＝ＣＨ、ＮＨ－ＣＨ２－ＣＨ２、ＣＯ－ＮＨ－ＣＨ２等を示し、；ＹはＣＨ又はＮを示し、；ＺはＣＨ２又はＯを示し、；Ｒ１は水素原子、ハロゲン原子、アルキル基、アルキルアミノカルボニル基等を示し、；Ｒ２はヒドロキシアルキル基、アルキルアミノ基、アルキルアミノカルボニル基、トリアゾリル基等を示し、；Ｒ３は水素原子、アルキル基等を示す。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007106917 | 2007-04-16 | ||
| JP2007-106917 | 2007-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008133129A1 true WO2008133129A1 (ja) | 2008-11-06 |
Family
ID=39925585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/057394 WO2008133129A1 (ja) | 2007-04-16 | 2008-04-16 | アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2008285478A (ja) |
| WO (1) | WO2008133129A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010524933A (ja) * | 2007-04-16 | 2010-07-22 | 参天製薬株式会社 | アデノシン誘導体を有効成分として含有する緑内障治療剤 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114025763B (zh) * | 2019-06-21 | 2023-09-12 | 中国人民解放军军事科学院军事医学研究院 | 腺苷类化合物、其可药用盐或其立体异构体及用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06128281A (ja) * | 1992-04-24 | 1994-05-10 | Whitby Res Inc | ヒドラゾアデノシン類 |
| WO2000012098A1 (fr) * | 1998-09-01 | 2000-03-09 | Yamasa Corporation | Compositions medicinales pour le traitement des maladies oculaires |
| JP2002518510A (ja) * | 1998-06-23 | 2002-06-25 | グラクソ グループ リミテッド | ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体 |
| JP2003506461A (ja) * | 1999-06-22 | 2003-02-18 | スィーヴィー セラピューティクス インコーポレイテッド | Ｎ−ピラゾールａ２ａ受容体アゴニスト |
| JP2004508284A (ja) * | 2000-02-18 | 2004-03-18 | ファイザー・インク | プリン誘導体 |
-
2008
- 2008-04-16 WO PCT/JP2008/057394 patent/WO2008133129A1/ja active Application Filing
- 2008-04-16 JP JP2008106283A patent/JP2008285478A/ja not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06128281A (ja) * | 1992-04-24 | 1994-05-10 | Whitby Res Inc | ヒドラゾアデノシン類 |
| JP2002518510A (ja) * | 1998-06-23 | 2002-06-25 | グラクソ グループ リミテッド | ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体 |
| WO2000012098A1 (fr) * | 1998-09-01 | 2000-03-09 | Yamasa Corporation | Compositions medicinales pour le traitement des maladies oculaires |
| JP2002173427A (ja) * | 1998-09-01 | 2002-06-21 | Yamasa Shoyu Co Ltd | 眼疾患治療用医薬組成物 |
| JP2003506461A (ja) * | 1999-06-22 | 2003-02-18 | スィーヴィー セラピューティクス インコーポレイテッド | Ｎ−ピラゾールａ２ａ受容体アゴニスト |
| JP2004508284A (ja) * | 2000-02-18 | 2004-03-18 | ファイザー・インク | プリン誘導体 |
Non-Patent Citations (3)
| Title |
|---|
| KONNO T. ET AL.: "Effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on ocular blood flow in rabbits", LIFE SCIENCE, vol. 80, no. 12, February 2007 (2007-02-01), pages 1115 - 1122, XP005891969 * |
| KONNO T.: "Role of adenosine in intraocular pressure", NIPPON YAKURIGAKU ZASSHI, vol. 123, no. 4, 2004, pages 289 - 294 * |
| MASAYUKI U. ET AL.: "2-Aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor", J. MED. CHEM., vol. 34, 1991, pages 1340 - 1344, XP002961133, DOI: doi:10.1021/jm00108a015 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010524933A (ja) * | 2007-04-16 | 2010-07-22 | 参天製薬株式会社 | アデノシン誘導体を有効成分として含有する緑内障治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008285478A (ja) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005080384A3 (en) | Benzimidazole derivative and use as aii receptor antagonist | |
| WO2005075458A8 (en) | Pyrimidine derivatives as orexin receptors antagonists | |
| MX2009013626A (es) | DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE. | |
| WO2008006043A3 (en) | 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents | |
| WO2002076950A3 (en) | Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors | |
| WO2008096829A1 (ja) | ３環系化合物 | |
| NO20060154L (no) | Imidazolyl-derivater | |
| WO2009072621A1 (ja) | 置換ジヒドロアゾール化合物及び有害生物防除剤 | |
| MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
| ATE388958T1 (de) | 4'-c-substituierte 2-haloadenosinderivate | |
| TW200738667A (en) | Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof | |
| WO2009035067A1 (ja) | １，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト | |
| RS51674B (en) | PIPERIDIN-4-IL-PIRIDAZIN-3-ILAMINE DERIVATIVES AS A FAST DISSOCATING DOPAMIN 2 RECEIVER ANTAGONISTS | |
| WO2009038064A1 (ja) | Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体 | |
| EP1854789A4 (en) | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | |
| WO2007017728A3 (en) | Novel heterocyclic compounds | |
| WO2009095792A3 (en) | Substituted heteroarylamide diazepinopyrimidone derivatives | |
| NO20072753L (no) | 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer | |
| MX2009011076A (es) | Agente terapeutico para glaucoma que contiene derivado de adenosina como ingrediente activo. | |
| WO2007144512A3 (fr) | Derivés diazeniumdiolates, leur procédé de préparation, leurs compositions pharmaceutiques et leur utilisation dans le domaine de l ' hypertension et des pathologies cardiovasculaires | |
| NZ552137A (en) | New 4-benzylidene-piperidin derivatives | |
| TW200606152A (en) | Piperidine compound and process for preparing the same | |
| WO2008149834A1 (ja) | ピリミドジアゼピノン誘導体 | |
| RS52518B (en) | 4-ALCOXYPYRIDASINE DERIVATIVES AS A FAST DISSOCATING DOPAMINE 2 RECEPTOR ANTAGONISTS | |
| WO2005003087A3 (en) | Oxazole derivatives as antibacterial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08740475 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08740475 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |